Skip to main content

OS Therapies Inc

OSTX
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001795091

No open-market purchases or sales by OS Therapies Inc insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q3 2026, worth $4.64M in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 17, 2026, 2:22 AM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of OS Therapies Inc, annual
Line itemFY2025FY2024
Period endDec 31, 2025Dec 31, 2024
Filing10-K10-K
Reported–Mar 31, 2025
Research and development$16.4M$2.84M
Selling, general and administrative$12.3M$3.97M
Operating income-$28.7M-$6.81M
Net income-$28.8M-$8.88M
EPS, basic$-0.98$-0.88
EPS, diluted$-0.98$-0.88
Weighted shares, basic–12.4M
Weighted shares, diluted29.3M–

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of OS Therapies Inc, annual
Line itemFY2025!FY2024!
Period endDec 31, 2025Dec 31, 2024
Filing10-K10-K
Reported–Mar 31, 2025
Cash and equivalents$269.8K$5.53M
Total current assets$332.9K$5.53M
Property, plant and equipment$2.49K$5.27K
Intangible assets$6.50M–
Total assets$6.84M$5.54M
Accounts payable$9.94M$1.66M
Total current liabilities$11.8M$4.63M
Total liabilities$11.9M$4.73M
Shareholders' equity-$6.10M-$5.24M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of OS Therapies Inc, annual
Line itemFY2025FY2024
Period endDec 31, 2025Dec 31, 2024
Filing10-K10-K
Reported–Mar 31, 2025
Operating cash flow-$14.2M-$7.28M
Capital expenditures$466.4K–
Free cash flow-$14.7M–
Depreciation and amortization$363.1K–
Stock-based compensation$4.27M$268.3K
Investing cash flow-$466.4K–
Financing cash flow$9.44M$12.8M

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for OS Therapies Inc by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 13, 202652.3M+48.5%SEC
Aug 12, 202646.1M+44.6%SEC
May 14, 202644.5M+58.5%SEC
Mar 26, 202639.5M+82.5%SEC
Nov 14, 202535.2M+65.8%SEC
Aug 13, 202531.9M+52.7%SEC
May 13, 202528.1M+134.5%SEC
Mar 28, 202521.7M+80.8%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
  • A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.